ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.